General MedicationsORALGeneric

LAMIVUDINE, NEVIRAPINE, AND STAVUDINE

LAMIVUDINE; NEVIRAPINE; STAVUDINE

Standard Dose

150MG; 200MG; 30MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: None (Tentative Approval)

Summary

Approval overview LAMIVUDINE, NEVIRAPINE, AND STAVUDINE is listed in Drugs@FDA under application 200244 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; NEVIRAPINE; STAVUDINE Form and strength TABLET; ORAL - 150MG; 200MG; 30MG Sponsor HETERO DRUGS LTD Submission history Latest submission status date: 2010-09-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE, NEVIRAPINE, AND STAVUDINE is listed in Drugs@FDA under application 200244 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; NEVIRAPINE; STAVUDINE Form and strength TABLET; ORAL - 150MG; 200MG; 30MG Sponsor HETERO DRUGS LTD Submission history Latest submission status date: 2010-09-10 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.